Close Menu

tuberculosis

China's food and drug regulator has cleared two microarray tests and an amplification test for identifying and differentiating tuberculosis.

The technology may enable a very stable diagnostic method to detect nucleic acids without using PCR, and has so far been demonstrated to detect anthrax.

BD and Tyrian ended their partnership to develop a point-of-care diagnostic for active tuberculosis because of an inability to consistently detect Tyrian's lead protein biomarker in clinical samples at high enough sensitivity and specificity levels.

The Swiss foundation has become a member of the CPGR in order to develop point-of-care tests for African diseases.

The test simultaneously identifies Mycobacterium tuberculosis and resistance to first-line drug therapy rifampicin.

Agilent's Human CNV Association 2x105K microarray, based on a design by the Wellcome Trust Case Control Consortium, is the company's second catalog CNV chip and was designed for studying associations between genomic CNVs and disease.

BioArray Briefs: 2009.04.07

Premium

CGC Genetics, Nuvera Biosciences, Veridex, ImaGenes, CapitalBio, Fisher Healthcare, Osmetech, National Institutes of Health, Clinical Data, Cogenics, UK Biotechnology and Biological Sciences Research Council

Several of the company's microarray-based tests have been certified in China and Europe.

Papers of Note: Mar 10, 2009

Premium

Sequencing-Related Papers of Note, Feb. 2009

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.